• PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseasesLankin, Vadim Z.; Tikhaze, Alla K.; Viigimaa, Margus; Chazova, Irina EvgenevnaTerapevticheskii Arkhiv2018 / p. 27-30 https://doi.org/10.26442/terarkh201890927-30 https://www.scopus.com/sourceid/19655 https://www.scopus.com/record/display.uri?eid=2-s2.0-85054532322&origin=resultslist&sort=plf-f&src=s&sid=453b52ade09d39dafbc80e3146572c7a&sot=b&sdt=b&s=DOI%2810.26442%2Fterarkh201890927-30%29&sl=36&sessionSearchId=453b52ade09d39dafbc80e3146572c7a&relpos=0 https://jcr.clarivate.com/jcr-jp/journal-profile?journal=TERAPEVT%20ARKH&year=2022 https://www.webofscience.com/wos/woscc/full-record/WOS:000450869600004